Abstract | BACKGROUND: METHODS: RESULTS: A wide range of GI(50) values was obtained for the cell lines, H2452 cells being the most sensitive (GI(50) 22 nM) and RS5 cells having a GI(50) value greater than 10 microM. No FRalpha protein was detected in any cell line, and there was no relationship between sensitivity and expression of folate transporters. FRalpha was detected in 39% of tumour samples, generally in a small percentage of cells. There was no correlation between the presence of FRalpha and the outcome of pemetrexed treatment, and no significant difference between histological subtypes. CONCLUSION: Response to treatment with pemetrexed does not depend on the presence of FRalpha.
|
Authors | J E Nutt, A R A Razak, K O'Toole, F Black, A E Quinn, A H Calvert, E R Plummer, J Lunec |
Journal | British journal of cancer
(Br J Cancer)
Vol. 102
Issue 3
Pg. 553-60
(Feb 02 2010)
ISSN: 1532-1827 [Electronic] England |
PMID | 20051956
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Carrier Proteins
- Folate Receptors, GPI-Anchored
- Folic Acid Antagonists
- Glutamates
- Receptors, Cell Surface
- Pemetrexed
- Guanine
|
Topics |
- Blotting, Western
- Carrier Proteins
(analysis, genetics, physiology)
- Cell Line, Tumor
- Folate Receptors, GPI-Anchored
- Folic Acid Antagonists
(therapeutic use)
- Glutamates
(therapeutic use)
- Guanine
(analogs & derivatives, therapeutic use)
- Humans
- Immunohistochemistry
- Mesothelioma
(drug therapy)
- Pemetrexed
- Pleural Neoplasms
(drug therapy)
- Receptors, Cell Surface
(analysis, genetics, physiology)
- Reverse Transcriptase Polymerase Chain Reaction
|